Changes in Forced Expiratory Volume in 1 Second over Time in COPD

被引:739
作者
Vestbo, Jorgen [1 ,2 ,3 ]
Edwards, Lisa D. [7 ]
Scanlon, Paul D. [9 ]
Yates, Julie C. [7 ]
Agusti, Alvar [10 ,11 ]
Bakke, Per [12 ]
Calverley, Peter M. A. [4 ]
Celli, Bartolome [13 ,14 ]
Coxson, Harvey O. [15 ]
Crim, Courtney [7 ]
Lomas, David A. [5 ]
MacNee, William [6 ]
Miller, Bruce E. [8 ]
Silverman, Edwin K. [13 ,14 ]
Tal-Singer, Ruth [8 ]
Wouters, Emiel [16 ]
Rennard, Stephen I. [17 ]
机构
[1] Univ Copenhagen, Hvidovre Hosp, Resp Sect, DK-2650 Hvidovre, Denmark
[2] Univ Copenhagen, Copenhagen, Denmark
[3] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[4] Univ Liverpool, Liverpool L69 3BX, Merseyside, England
[5] Univ Cambridge, Cambridge, England
[6] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[7] GlaxoSmithKline Inc, Res Triangle Pk, NC USA
[8] GlaxoSmithKline Inc, King Of Prussia, PA USA
[9] Mayo Clin, Rochester, MN USA
[10] Univ Barcelona, Thorax Inst, Hosp Clin, Inst Invest Biomed August Pi & Sunyer, Barcelona, Spain
[11] CIBER Enfermedades Resp, Palma De Mallorca, Mallorca, Spain
[12] Univ Bergen, Inst Internal Med, Bergen, Norway
[13] Brigham & Womens Hosp, Boston, MA 02115 USA
[14] Harvard Univ, Sch Med, Boston, MA USA
[15] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[16] Univ Maastricht, Maastricht, Netherlands
[17] Univ Nebraska Med Ctr, Omaha, NE USA
关键词
OBSTRUCTIVE PULMONARY-DISEASE; AIR-FLOW OBSTRUCTION; LUNG-FUNCTION; NATURAL-HISTORY; ECLIPSE COHORT; DECLINE; EXACERBATION; EPIDEMIOLOGY; PROPIONATE; HEALTH;
D O I
10.1056/NEJMoa1105482
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND A key feature of chronic obstructive pulmonary disease (COPD) is an accelerated rate of decline in forced expiratory volume in 1 second (FEV(1)), but data on the variability and determinants of this change in patients who have established disease are scarce. METHODS We analyzed the changes in FEV1 after administration of a bronchodilator over a 3-year period in 2163 patients. A random-coefficient model was used to evaluate possible predictors of both FEV1 levels and their changes over time. RESULTS The mean (+/- SE) rate of change in FEV1 was a decline of 33 +/- 2 ml per year, with significant variation among the patients studied. The between-patient standard deviation for the rate of decline was 59 ml per year. Over the 3-year study period, 38% of patients had an estimated decline in FEV1 of more than 40 ml per year, 31% had a decline of 21 to 40 ml per year, 23% had a change in FEV1 that ranged from a decrease of 20 ml per year to an increase of 20 ml per year, and 8% had an increase of more than 20 ml per year. The mean rate of decline in FEV1 was 21 +/- 4 ml per year greater in current smokers than in current nonsmokers, 13 +/- 4 ml per year greater in patients with emphysema than in those without emphysema, and 17 +/- 4 ml per year greater in patients with bronchodilator reversibility than in those without reversibility. CONCLUSIONS The rate of change in FEV1 among patients with COPD is highly variable, with increased rates of decline among current smokers, patients with bronchodilator reversibility, and patients with emphysema. (Funded by GlaxoSmithKline; ECLIPSE-ClinicalTrials.gov number, NCT00292552.)
引用
收藏
页码:1184 / 1192
页数:9
相关论文
共 24 条
[1]   Characterisation of COPD heterogeneity in the ECLIPSE cohort [J].
Agusti, Alvar ;
Calverley, Peter M. A. ;
Celli, Bartolome ;
Coxson, Harvey O. ;
Edwards, Lisa D. ;
Lomas, David A. ;
MacNee, William ;
Miller, Bruce E. ;
Rennard, Steve ;
Silverman, Edwin K. ;
Tal-Singer, Ruth ;
Wouters, Emiel ;
Yates, Julie C. ;
Vestbo, Jorgen .
RESPIRATORY RESEARCH, 2010, 11
[2]  
[Anonymous], 2016, Fact Sheet
[3]   Bronchodilator response in the lung health study over 11 yrs [J].
Anthonisen, NR ;
Lindgren, PG ;
Tashkin, DP ;
Kanner, RE ;
Scanlon, PD ;
Connett, JE .
EUROPEAN RESPIRATORY JOURNAL, 2005, 26 (01) :45-51
[4]   Epidemiology of chronic obstructive pulmonary disease [J].
Antó, JM ;
Vermeire, P ;
Vestbo, J ;
Sunyer, J .
EUROPEAN RESPIRATORY JOURNAL, 2001, 17 (05) :982-994
[5]  
Bridevaux PO, 2008, THORAX, V63, P768, DOI 10.1136/thx.2007.093724
[6]   Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA Cohort Study [J].
Brutsche, M. H. ;
Downs, S. H. ;
Schindler, C. ;
Gerbase, M. W. ;
Schwartz, J. ;
Frey, M. ;
Russi, E. W. ;
Ackermann-Liebrich, U. ;
Leuenberger, P. .
THORAX, 2006, 61 (08) :671-677
[7]   Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [J].
Calverley, Peter M. A. ;
Anderson, Julie A. ;
Celli, Bartolome ;
Ferguson, Gary T. ;
Jenkins, Christine ;
Jones, Paul W. ;
Yates, Julie C. ;
Vestbo, Jorgen ;
Calverley, P. M. A. ;
Anderson, J. A. ;
Celli, B. ;
Ferguson, G. T. ;
Jenkins, C. ;
Jones, P. W. ;
Knobil, K. ;
Yates, J. C. ;
Vestbo, J. ;
Cherniack, R. ;
Similowski, T. ;
Cleland, J. ;
Whitehead, A. ;
Wise, R. ;
McGarvey, L. ;
John, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :775-789
[8]   Bronchodilator reversibility testing in chronic obstructive pulmonary disease [J].
Calverley, PMA ;
Burge, PS ;
Spencer, S ;
Anderson, JA ;
Jones, PW .
THORAX, 2003, 58 (08) :659-664
[9]   Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease - Results from the TORCH study [J].
Celli, Bartolome R. ;
Thomas, Nicola E. ;
Anderson, Julie A. ;
Ferguson, Gary T. ;
Jenkins, Christine R. ;
Jones, Paul W. ;
Vestbo, Jorgen ;
Knobil, Katharine ;
Yates, Julie C. ;
Calverley, Peter M. A. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 178 (04) :332-338
[10]   Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial [J].
Decramer, Marc ;
Celli, Bartolome ;
Kesten, Steven ;
Lystig, Theodore ;
Mehra, Sunil ;
Tashkin, Donald P. .
LANCET, 2009, 374 (9696) :1171-1178